Children
A paediatric formulation of tipranavir (Aptivus) is available. Boehringer Ingelheim has reported that a dose of 290mg/m2 tipranavir boosted by 115mg/m2 ritonavir in children brings about similar levels of tipranavir in the blood to the standard adult dose[1].
A study of 115 HIV-positive children aged between two and 18 years has found that this dose, or the higher dose of 375 / 150 mg/m2 resulted in viral loads below 50 copies/ml in 35% of the children after 48 weeks. This was coupled with CD4 cell count increases of 157 and 96 cells/mm3 respectively. All but three of the children were treatment-experienced, with the older children having a median of 17 protease inhibitor-associated mutations[2].
latest aidsmap news
- Taking charge of TB services for people with HIV
- Programmes gradually adopting TB/HIV activities, as funding and technical partners harmonise monitoring and evaluation
- Programmes begin to nurture much needed TB/HIV advocacy
- Gilead now testing ritonavir replacement in human studies
- Parasitic worm increases HIV infection risk
- Low level of drug-resistant strains common in untreated patients, but may not affect treatment
- HIV persists in the breastmilk of HIV-positive Kenyan mothers on antiretroviral treatment
- Herpes simplex virus type 2 reactivations contribute to genital and plasma HIV-1 shedding
- Gene that protects against malaria may increase HIV risk in Africans
- Gay men’s HIV prevention in UK must focus on men under 30 and those with large numbers of sexual partners, says Sigma Research